Objective: Here, we present a cohort study of 46 KTR who developed COVID-19 infection. We detailed demographics, immunosuppression regimen, clinical profile, treatment, and outcomes.  Methods: Median age of transplant recipients was 41 years, and recipients presented at a median of 2.9 years after transplant. Most common comorbidities (94%) included arterial hypertension (71%) and diabetes (35.7%); presenting symptoms at the time of COVID-19 included fever (92.8%), breathlessness (64.3%) and cough (57.1%). Clinical severity ranged from asymptomatic (12%), mild (38%), and moderate (24%) to severe (29%). Strategies to modify immunosuppressants included discontinuation of antimetabolites without changes in calcineurin inhibitors and steroids (64.3%). Risk factors for mortality included older age, severe disease, allograft dysfunction before COVID-19 infection; acute kidney injury; higher levels of inflammatory markers including C-reactive protein, interleukin-6 level, and procalcitonin; and higher computerised tomography severity index (CTSI). Acute kidney injury developed in 57.1% of patients out of which dialysis was needed in 14.3%. Overall patient mortality was 14.3%. At 3 months of follow up, loss of graft function was seen in 7.1% of patients.  Results: Mortality rates in COVID-19-positive KTR appear to be higher than those in nonimmunosuppressed patients Conclusions: Objective: To study the Clinical profile and outcome of coronavirus disease-19 (COVID-19) infections in kidney transplant recipients (KTR)   Methods: Here, we present a cohort study of 46 KTR who developed COVID-19 infection. We detailed demographics, immunosuppression regimen, clinical profile, treatment, and outcomes.  Results: Median age of transplant recipients was 41 years, and recipients presented at a median of 2.9 years after transplant. Most common comorbidities (94%) included arterial hypertension (71%) and diabetes (35.7%); presenting symptoms at the time of COVID-19 included fever (92.8%), breathlessness (64.3%) and cough (57.1%). Clinical severity ranged from asymptomatic (12%), mild (38%), and moderate (24%) to severe (29%). Strategies to modify immunosuppressants included discontinuation of antimetabolites without changes in calcineurin inhibitors and steroids (64.3%). Risk factors for mortality included older age, severe disease, allograft dysfunction before COVID-19 infection; acute kidney injury; higher levels of inflammatory markers including C-reactive protein, interleukin-6 level, and procalcitonin; and higher computerised tomography severity index (CTSI). Acute kidney injury developed in 57.1% of patients out of which dialysis was needed in 14.3%. Overall patient mortality was 14.3%. At 3 months of follow up, loss of graft function was seen in 7.1% of patients.  Conclusions: Mortality rates in COVID-19-positive KTR appear to be higher than those in nonimmunosuppressed patients